First‐line or second‐line PD‐1 inhibition in advanced oesophageal squamous cell carcinoma: A prospective, multicentre, registry study.
What is known and objective: First‐line and second‐line immunotherapy with programmed death‐1 (PD‐1) inhibitors both improve overall survival in patients with advanced oesophageal squamous cell cancer (ESCC). This study explored survival differences between first‐line and second‐line PD‐1 inhibition...
| Published in: | Journal of Clinical Pharmacy & Therapeutics Vol. 47; no. 6; pp. 732 - 738 |
|---|---|
| Main Authors: | , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Wiley-Blackwell
Jun2022
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157510393&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 157510393 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Jun2022 vid: 47 iid: 6 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 157510393 154419038 157510393 157510393 10.1111/jcpt.13599 157510393 ppf: 732 ppct: 6 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: First‐line or second‐line PD‐1 inhibition in advanced oesophageal squamous cell carcinoma: A prospective, multicentre, registry study. aug: au: Li, Xu‐Yuan Huang, Li‐Sheng Cai, Hao‐Quan Huang, Wan‐Lan Huang, Xiao‐Long affil: Department of Medical Oncology, Shantou Central Hospital, Shantou, China sug: subj: Esophageal Squamous Cell Carcinoma Drug Therapy Programmed Cell Death Protein 1 Receptor Therapeutic Use Esophageal Squamous Cell Carcinoma Prognosis Immunotherapy Methods Human Prospective Studies Multicenter Studies Progression-Free Survival Comparative Studies Log-Rank Test Descriptive Statistics ab: What is known and objective: First‐line and second‐line immunotherapy with programmed death‐1 (PD‐1) inhibitors both improve overall survival in patients with advanced oesophageal squamous cell cancer (ESCC). This study explored survival differences between first‐line and second‐line PD‐1 inhibition in advanced ESCC. Methods: This registry study included 167 patients with advanced ESCC who were exposed to PD‐1 inhibitors in either a first‐line or a second‐line setting between 15 January 2019 and 31 October 2020. The primary endpoint was overall survival, and secondary endpoints included overall tumour response, progression‐free survival (PFS) and PFS2. A propensity score‐matching (PSM) analysis was performed using the nearest‐neighbour method. Results and discussion: Sixty‐one patients started first‐line treatment with chemotherapy and a PD‐1 inhibitor (Group 1), while 106 started chemotherapy as the first‐line choice and received a PD‐1 inhibitor as the second‐line choice (Group 2). The median PFS was 7.1 months in Group 1 and 4.1 months in Group 2 (log‐rank p = 0.001). The median PFS2 was 7.1 months in Group 1 and 7.4 months in Group 2 (log‐rank p = 0.4). Before PSM, the median overall survival was 13.5 months in Group 1 and 14.1 months in Group 2 (log‐rank p = 0.9), and the sensitivity analysis showed consistent results (14.0 vs. 14.1 months). After PSM, the median overall survival rates for Group 1 (n = 61) and Group 2 (n = 61) were 13.5 and 13.1 months (log‐rank p = 0.7) respectively. What is new and conclusion: In this study, patients with advanced ESCC who received first‐line or second‐line PD‐1 inhibitors seemed to have comparable overall survival. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|